A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia
- PMID: 20200930
- DOI: 10.1002/jbmr.15
A nonsecosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia
Abstract
Vitamin D(3) analogues were shown to be beneficial for osteoporosis and other indications, but their narrow therapeutic window between efficacy and hypercalcemia has limited their clinical utility. A nonsecosteroidal, tissue-selective, orally bioavailable, vitamin D receptor (VDR) ligand was ascertained to be efficacious in bone while having modest calcemic effects in vivo. This compound (VDRM2) potently induced Retinoid X Receptor alpha (RXR)-VDR heterodimerization (EC(50) = 7.1 +/- 1.6 nM) and induced osteocalcin promoter activity (EC(50) = 1.9 +/- 1.6 nM). VDRM2 was less potent in inducing Ca(2+) channel transient receptor potential cation channel, subfamily V, member 6 (TRPV6) expression (EC(50) = 37 +/- 12 nM). VDRM2 then was evaluated in osteopenic ovariectomized (OVX) rats and shown to dose-dependently restore vertebral bone mineral density (BMD) from OVX to sham levels at 0.08 microg/kg per day. Hypercalcemia was observed at a dose of 4.6 microg/kg per day of VDRM2, suggesting a safety margin of 57 [90% confidence interval (CI) 35-91]. 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D], ED71, and alfacalcidol restored BMD at 0.030, 0.0055, and 0.046 microg/kg per day, respectively, whereas hypercalcemia was observed at 0.22, 0.027, and 0.23 microg/kg per day, indicating a safety margin of 7.3, 4.9, and 5.0, respectively (90% CIs 4.1-13, 3.2-7.7, and 3.5-6.7, respectively). Histomorphometry showed that VDRM2 increased cortical bone area and stimulated the periosteal bone-formation rate relative to OVX at doses below the hypercalcemic dose. By contrast, ED71 increased the periosteal bone-formation rate only above the hypercalcemic dose. VDRM2 suppressed eroded surface on trabecular bone surfaces at normal serum calcium dosage levels, suggesting dual anabolic and antiresorptive activity. In summary, vitamin D analogues were more potent than VDRM2, but VDRM2 had a greater safety margin, suggesting possible therapeutic potential.
(c) 2010 American Society for Bone and Mineral Research.
Similar articles
-
A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.J Bone Miner Res. 2005 Oct;20(10):1742-55. doi: 10.1359/JBMR.050605. Epub 2005 Jun 13. J Bone Miner Res. 2005. PMID: 16160732
-
The vitamin D hormone and its nuclear receptor: molecular actions and disease states.J Endocrinol. 1997 Sep;154 Suppl:S57-73. J Endocrinol. 1997. PMID: 9379138 Review.
-
1 Alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats.Bone. 2004 Sep;35(3):704-10. doi: 10.1016/j.bone.2004.04.011. Bone. 2004. PMID: 15336607
-
1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.J Bone Miner Res. 2001 Apr;16(4):639-51. doi: 10.1359/jbmr.2001.16.4.639. J Bone Miner Res. 2001. PMID: 11315991
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics.Immunol Rev. 2015 Mar;264(1):344-62. doi: 10.1111/imr.12255. Immunol Rev. 2015. PMID: 25703571 Free PMC article. Review.
-
Effects of Calcium, Vitamin D, and Hormone Therapy on Cardiovascular Disease Risk Factors in the Women's Health Initiative: A Randomized Controlled Trial.Obstet Gynecol. 2017 Jan;129(1):121-129. doi: 10.1097/AOG.0000000000001774. Obstet Gynecol. 2017. PMID: 27926633 Free PMC article. Clinical Trial.
-
Effect of Calcitriol and Vitamin D Receptor Modulator 2 on Recovery of Injured Skeletal Muscle in Wistar Rats.Biomedicines. 2023 Sep 7;11(9):2477. doi: 10.3390/biomedicines11092477. Biomedicines. 2023. PMID: 37760917 Free PMC article.
-
The role of TRPV channels in osteoporosis.Mol Biol Rep. 2022 Jan;49(1):577-585. doi: 10.1007/s11033-021-06794-z. Epub 2021 Oct 25. Mol Biol Rep. 2022. PMID: 34694549 Review.
-
Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism.Br J Pharmacol. 2018 Jan;175(2):262-271. doi: 10.1111/bph.14028. Epub 2017 Nov 28. Br J Pharmacol. 2018. PMID: 28898923 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous